New device could more effectively alleviate menstrual cramp pain

Sep 21, 2009

While most women experience minor pain during menstruation, for others, the pain can be severe enough to interfere with everyday activities and require medication. New research to be presented at the 2009 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition will reveal initial findings of safety surrounding a new device that may more effectively treat menstrual pain.

"The goal of our study was to find a better way to treat menstrual cramps," said Giovanni M. Pauletti, Ph.D., associate professor at the University of Cincinnati and the study's presenter as well as past chair of AAPS' National Biotechnology Conference Planning Committee. "Existing oral medications cause significant gastrointestinal side effects for women, creating additional discomfort while alleviating menstrual pain. Results from our Phase I clinical trials show that this new vaginal device safely delivers at least 10-times more drug to the uterus as a tablet of equivalent dose."

The study, which was sponsored by UMD, Inc., a Cincinnati drug delivery company, and conducted at Women's Health Research, Inc. involved 18 study participants, aged 18-45 years with menstrual cycles between 25-30 days. During the mid-follicular phase of the first menstrual cycle (days 7-11), nine study participants received an oral dose of 10 mg of ketorolac (Toradol®), a non-steroidal anti-inflammatory medication; while nine women received a tampon coated with 10 mg of ketorolac. During the second menstrual cycle, each subject received the opposite treatment.

The results of the study demonstrated that the medication administered vaginally does not cause significant side effects but accumulates more efficiently in the desired uterine tissue than using the oral medication.

"While still early in our research, this study shows promising results which may help pave the way for new treatment options for women," said Pauletti. "Phase II clinical trials will study efficacy of the treatment to assess whether the drug concentration is effective in reducing pain."

Source: American Association of Pharmaceutical Scientists

Explore further: Drug for rare blood disorder developed at Penn receives orphan drug status from EU

add to favorites email to friend print save as pdf

Related Stories

New study: Pine bark significantly reduces menstrual pain

Jun 18, 2008

A new study reveals dysmenorrhea, a condition that causes extremely painful menstrual periods affecting millions of women each year, can be reduced naturally by taking Pycnogenol (pic-noj-en-all), pine bark extract from the ...

Premenstrual symptoms getting on your nerves?

Dec 20, 2007

For some women premenstrual syndrome (PMS) is a minor monthly annoyance, but for others, more severe symptoms seriously disrupt their lives. However despite the number of women affected, science has yet to offer a full explanation ...

Brain images show menstrual cycle rhythms

Oct 24, 2005

Cornell University scientists say women with no menstrual mood changes may use parts of their brains differently over the course of their menstrual cycles.

Scientists identify possible cause of endometriosis

Aug 05, 2008

Endometriosis is a condition whereby patches of the inner lining of the womb appear in parts of the body other than the womb cavity. It can cause severe pain and affects approximately 15% of women of reproductive ...

Recommended for you

Using computers to design drugs

Aug 22, 2014

Designing a new medicine is an expensive and time consuming business. Typically it takes around $2 billion and ten years for a new drug to move from its initial design in the lab, to the clinic. All the ...

Lilly psoriasis drug fares well in late-stage test

Aug 22, 2014

Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.

New US restrictions on painkiller to take effect

Aug 21, 2014

The federal government is finalizing new restrictions on hundreds of medicines containing hydrocodone, the highly addictive painkiller that has grown into the most widely prescribed drug in the U.S.

User comments : 0